ml8b00172_si_001.pdf (82.01 kB)

Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI

Download (82.01 kB)
journal contribution
posted on 06.06.2018, 00:00 by Nadia R. Ayat, Jing-Can Qin, Han Cheng, Sarah Roelle, Songqi Gao, Yajuan Li, Zheng-Rong Lu
The aim of this work is to optimize a peptide targeted macrocyclic MRI contrast agent for detection and risk-stratification of aggressive prostate cancer. The optimized agent was prepared using click chemistry in the presence of CuSO4 and ascorbate at room temperature. The T1 and T2 relaxivities of ZD2-N3-Gd­(HP-DO3A) are 5.44 and 7.10 mM–1 s–1 at 1.4 T, and 5.53 and 7.81 mM–1 s–1 at 7 T, respectively, higher than the previously reported ZD2-Gd­(HP-DO3A). The specific tumor enhancement of the agent was investigated in male nude mice bearing aggressive PC3 human prostate cancer xenografts and slow-growing LNCaP tumor xenografts. Contrast enhanced MR images were acquired using a 2D spin–echo sequence and a 3D FLASH sequence with a 7 T small animal scanner. ZD2-N3-Gd­(HP-DO3A) produced robust contrast enhancement in aggressive PC3 tumors and little enhancement in slow-growing LNCaP tumors. It produced 400% and 100% CNR increases in the T1-weighted 2D spin–echo MR images and 3D FLASH images of PC3 tumors, respectively, for at least 30 min at a dose of 0.1 mmol/kg. In contrast, less than 20% CNR increase was observed in the LNCaP tumors with both sequences. The optimized targeted contrast agent has higher relaxivities and are effective to detect aggressive PC3 tumors and differentiate the aggressive cancer from the slow-growing LNCaP prostate cancer in contrast enhanced MRI. ZD2-N3-Gd­(HP-DO3A) has the promise for accurate detection and risk-stratification of aggressive prostate cancer.

History